Pyxis Oncology closed at $1.66 on Nov 4, up 1.22%, 68.9% below its 52-week closing high. Volume of 924.3K shares was 1.11× its 20-day average (close to normal).
Split-adjusted performance: -17.8% over one month, -27.8% over six months, -56.4% over one year.
Short interest was 4.3M shares at the Oct 15 settlement, down 11.1% from the prior report (7.9% of float, 3.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PYXSPyxis Oncology | $1.66 | +1.22% | −27.8% | −100.0% | — | — | $138.5M | |
| SPRBSpruce Biosciences | $46.61 | +8.88% | −19.5% | — | — | — | $134.0M | Compare |
| DERMJourney Medical | $4.73 | +1.94% | −9.2% | +18.9% | −1.7% | — | $133.5M | Compare |
| CUECue Biopharma | $19.84 | −4.89% | −41.6% | +166.7% | −1943.2% | — | $144.1M | Compare |
| MGNXMacroGenics | $2.31 | −0.86% | −23.3% | +378.0% | 59.4% | — | $147.1M | Compare |
| RNAAtrium Therapeutics | $8.68 | −0.46% | −33.7% | −21.9% | −672.0% | — | $148.5M | Compare |
| YARWYarrow Bioscience | $14.91 | −18.84% | — | — | — | — | $125.8M | Compare |
| FHTXFoghorn Therapeutics | $2.10 | −1.41% | −55.1% | +112.7% | −44.7% | — | $124.7M | Compare |
| NKTXNkarta | $1.73 | +13.07% | −47.9% | — | — | — | $123.9M | Compare |
No recent articles focused on Pyxis Oncology.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
